Enanta Pharmaceuticals Inc (ENTA.OQ)
12 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|73||2015||Chairman of the Board,Independent Director|
|60||2003||President, Chief Executive Officer, Director|
|61||2003||Chief Financial Officer, Senior Vice President - Finance & Administration|
|64||1999||Senior Vice President - Research & Development, Chief Scientific Officer|
|63||2014||Senior Vice President, General Counsel|
- BRIEF-Enanta Pharma Says Abbvie’s Maviret is Now Commercially Available In Japan
- BRIEF-Enanta Pharma Q4 earnings per share $1.86
- BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist
- BRIEF-Enanta Pharmaceuticals announces new data presentations on EDP-305
- BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c